Hormone-receptor-positive advanced breast cancer
1 paper
- Human trial1
Latest
Advances in Therapy
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis
Randomised trial in peoplemTOR inhibitors
The New England Journal of Medicine
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
Randomised trial in 724 peopleBreast cancer